丙型肝炎病毒感染与治疗药物  

Hepatitis C virus infection and its therapeutic drugs

作　　者：戚中田[1] 

机构地区：[1]第二军医大学微生物教研室,上海200433

出　　处：《临床肝胆病杂志》2011年第1期15-18,27,共5页Journal of Clinical Hepatology

基　　金：国家传染病重大专项课题(2008ZX10002-013);国家新药创制重大专项课题(2008ZXJ09009-002);上海市重点学科建设项目(B901)

摘　　要：丙型肝炎病毒(HCV)通过在宿主细胞内持续复制,导致慢性感染。目前用于治疗慢性丙型肝炎(CHC)的药物主要是聚乙二醇干扰素(PEG-IFN)和利巴韦林的联合用药。本文将就HCV的细胞入侵、复制、逃避宿主的固有和获得性免疫,以及抗HCV临床试验药物的最新进展做一综述。Hepatitis C virus（HCV） can lead to chronic hepatitis C（CHC） in ways that favor viral replication and persistent infection.The current standard treatment for hepatitis C virus infection is the combination of pegylated IFN with ribavirin（PEG-IFN/RBV）.In the recent years there has been significant advances in the understanding of viral replication and the development of anti-virus agents.This review summarizes the current knowledge of HCV cell entry,replication,escaping host innate and adaptive immune responses and current clinical trails of anti-HCV drugs.

关 键 词：肝炎 丙型 肝炎病毒属 

分 类 号：R512.63[医药卫生—内科学]